RSS

PLOS ONE

Biopharmaceutical company, Sucampo Pharmaceuticals, has announced the publication of a study in PLOS ONE that confirms the composition of VTS-270, which is currently under investigation for the treatment of Niemann-Pick Disease Type C1 (NPC-1). more

News